Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECONGEST: Diuretic Treatment in Acute Heart Failure Guided by Urine Sodium
NCT05411991Phase 4Completed
- Sponsor
- Vrije Universiteit Brussel
- Start
- Jun 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of acetazolamide, bumetanide, chlorthalidone and potassium canrenoate in Acute Heart Failure (AHF) (2 arms), sponsored by Vrije Universiteit Brussel. Primary endpoint: Mortality, Days in Hospital & Decongestion at 30 days. Started Jun 2022; status: completed.
02
Drugs
acetazolamidebumetanidechlorthalidonepotassium canrenoate
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on NCT05411991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05411991.